Strategic partnerships HiFiBiO actively collaborates with major multinational pharmaceutical and biotech companies leveraging its DIS technology, signaling strong open-door potential for co-development, license, or collaboration partnerships in immunotherapy targets and biomarkers.

Clinical-stage momentum As a clinical-stage global biotech with an advancing immunotherapy pipeline, HiFiBiO presents near-term collaboration opportunities for joint clinical programs, CRO/CMC support, and translational science partnerships to de-risk development milestones.

Target discovery focus DIS® technology combines single-cell analytics with AI/ML on patient samples to discover targets and predictive biomarkers, offering opportunities to integrate your company’s target validation platforms or biomarker assays into HiFiBiO’s translational workflow.

Geographic reach With sites in Cambridge (MA), Paris, Hong Kong, Shanghai, and Hangzhou, HiFiBiO’s global footprint enables regional business development, clinical collaboration, and access to diverse patient cohorts and regulatory landscapes.

Recognition and leadership Recent SAB appointments and Fierce 15 recognition highlight industry validation and leadership in inflammation and immunology, suggesting value in strategic advisory roles, co-authored publications, and joint scientific events to accelerate visibility and deal flow.